Furthermore, auto-antibodies target immune-related proteins including those involved in lymphocyte function and activation, leukocyte trafficking, the type I and type III IFN responses, type II immunity and the acute phase response increase in patients with severe COVID-19. The gene discussed is IFNA1; the disease is COVID-19.